Patient Perspective on Cross-Linking

Learn more about the importance of early diagnosis and treatment from a keratoconus patient and her treating physician.

A General Overview

Corneal cross-linking is a minimally invasive outpatient procedure that combines the use of Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and the KXL® system for the treatment of progressive keratoconus.

Corneal Cross-Linking: A New Standard of Care for Progressive Keratoconus

Corneal collagen cross-linking is an innovative therapy that has transformed the treatment of progressive keratoconus. Historically, as many as 1 in 5 patients with progressive keratoconus have required a corneal transplant, with more than half needing multiple transplants within 20 years.1, 2

¹Pramanik S, Musch DC, Sutphin JE, Farjo AA. Extended long-term outcomes of penetrating keratoplasty for keratoconus. Ophthalmology 2006;113(9):1633-8.
2Maharana PK, Agarwal K, Jhanji V, Vajpayee RB. Deep anterior lamellar keratoplasty for keratoconus: a review. Eye Contact Lens 2014;40(6):382-9.

Top Questions to Ask Your Eye Doctor Download PDF

FDA Approval

The first and only therapeutic products for corneal cross-linking which have been FDA approved to treat progressive keratoconus.

In April 2016, the FDA approved Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and the KXL® System for corneal cross-linking, a minimally invasive outpatient procedure that combines the use of Vitamin B2 eye drops and ultra-violet (UV) light.

The approval of Photrexa Viscous, Photrexa and the KXL System offers an effective treatment for patients who, until recently, had no therapeutic options to limit the progression of this sight-threatening disease.


Learn more about this outpatient procedure

View our Living with Keratoconus Patient Brochure.

Patient FAQs

Discover answers to the most common questions surrounding cross-linking

Visit the Patient FAQ Section to learn more.

It is estimated that...

1 Out of Every 2,000

persons in the general population have Keratoconus1

You can find more information from the National Keratoconus Foundation.

1. Kennedy R. H., Bourne W. M., Dyer J. A. A 48-year clinical and epidemiologic study of keratoconus. The American Journal of Ophthalmology. 1986;101(3):267–273. doi: 10.1016/0002-9394(86)90817-2.

Corneal cross-linking provides patients a much-needed option to treat this debilitating disease. Patients suffering from progressive keratoconus can now receive a therapeutic treatment that has been rigorously tested and approved."

Mary Prudden, Executive Director for the National Keratoconus Foundation

What are Patients Saying? View Stories

Learn More Through Our Facebook Page

Unable to display Facebook posts.
Show error

Error: (#4) Application request limit reached
Type: OAuthException
Code: 4
Please refer to our Error Message Reference.

Learn More Through Our Twitter Page

Have you heard of the National Keratoconus Foundation? The NKCF's website is a great resource for information on #keratoconus, treatment options, and upcoming events!

Did you know that FDA approved #crosslinking is now widely covered by insurance? Visit our website to see if your insurance plan is on the list!

#EyeSafety tip: Practice workplace eye safety — wear protective eyewear when necessary. More #HealthyVision tips: #NSM

June is Migraine and Headache Awareness Month! If you're #LivingWithKC, did you suffer from headaches before and/or after you were diagnosed? #mham

#ICYMI - @BaltSunSports highlighted Brandon Williams' journey with #keratoconus and how he is able to remain on the field with the Baltimore Ravens @BrandonW_66

Load More...

Learn More Through Our Instagram